Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul N Durrington

Showing results (11-20 of 106) with videos related to

Pageof 11
Sort By:
Atherosclerosis|April 3, 2021
Cholesterol lowering in secondary prevention: Could do betterPaul N Durrington, Handrean Soran
Drugs|January 11, 2007
Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potentialValentine Charlton-Menys, Paul N Durrington
Clinical Chemistry|February 1, 2005
Apolipoprotein A5 and hypertriglyceridemiaValentine Charlton-Menys, Paul N Durrington
BMJ (Clinical Research Ed.)|August 23, 2008
Hypercholesterolaemia and its managementDeepak Bhatnagar, Handrean Soran, Paul N Durrington
Current Opinion in Lipidology|September 9, 2022
What should be the goal of cholesterol-lowering treatment? A quantitative evaluation dispelling guideline mythsPaul N Durrington, Bilal Bashir, Handrean Soran
Atherosclerosis|December 12, 2018
Reply to: "Comments on 'Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk' "Handrean Soran, Safwaan Adam, Paul N Durrington
European Journal of Preventive Cardiology|September 10, 2016
Are recent statin recommendations to employ fixed doses and abandon targets effective for treatment of hypercholesterolaemia? Investigation based on number needed to treatHandrean Soran, Safwaan Adam, Paul N Durrington
Frontiers in Cardiovascular Medicine|March 6, 2023
Paraoxonase 1 and atherosclerosisPaul N Durrington, Bilal Bashir, Handrean Soran
Atherosclerosis|October 2, 2018
Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease riskHandrean Soran, Safwaan Adam, Paul N Durrington
Antioxidants (Basel, Switzerland)|April 29, 2025
How Does HDL Participate in Atherogenesis? Antioxidant Activity Versus Role in Reverse Cholesterol TransportPaul N Durrington, Bilal Bashir, Handrean Soran
Pageof 11

Showing results (11-20 of 106) with videos related to

Sort By:
Pageof 11
Atherosclerosis|April 3, 2021
Cholesterol lowering in secondary prevention: Could do betterPaul N Durrington, Handrean Soran
Drugs|January 11, 2007
Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potentialValentine Charlton-Menys, Paul N Durrington
Clinical Chemistry|February 1, 2005
Apolipoprotein A5 and hypertriglyceridemiaValentine Charlton-Menys, Paul N Durrington
BMJ (Clinical Research Ed.)|August 23, 2008
Hypercholesterolaemia and its managementDeepak Bhatnagar, Handrean Soran, Paul N Durrington
Current Opinion in Lipidology|September 9, 2022
What should be the goal of cholesterol-lowering treatment? A quantitative evaluation dispelling guideline mythsPaul N Durrington, Bilal Bashir, Handrean Soran
Atherosclerosis|December 12, 2018
Reply to: "Comments on 'Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk' "Handrean Soran, Safwaan Adam, Paul N Durrington
European Journal of Preventive Cardiology|September 10, 2016
Are recent statin recommendations to employ fixed doses and abandon targets effective for treatment of hypercholesterolaemia? Investigation based on number needed to treatHandrean Soran, Safwaan Adam, Paul N Durrington
Frontiers in Cardiovascular Medicine|March 6, 2023
Paraoxonase 1 and atherosclerosisPaul N Durrington, Bilal Bashir, Handrean Soran
Atherosclerosis|October 2, 2018
Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease riskHandrean Soran, Safwaan Adam, Paul N Durrington
Antioxidants (Basel, Switzerland)|April 29, 2025
How Does HDL Participate in Atherogenesis? Antioxidant Activity Versus Role in Reverse Cholesterol TransportPaul N Durrington, Bilal Bashir, Handrean Soran
Pageof 11